Jasper Therapeutics, Inc. (JSPR)
NCM – Real Time Price. Currency in USD
0.91
-0.03 (-3.15%)
At close: May 12, 2026, 4:00 PM EDT
0.91
0.00 (0.00%)
After-hours: May 12, 2026, 7:23 PM EDT
Find any stock by ticker or company name

NCM – Real Time Price. Currency in USD
0.91
-0.03 (-3.15%)
At close: May 12, 2026, 4:00 PM EDT
0.91
0.00 (0.00%)
After-hours: May 12, 2026, 7:23 PM EDT
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
| Name | Position |
|---|---|
| Alex Gray | Head of Investor Relations |
| Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder, Member of Scientific Advisory Board & Director |
| Dr. Luca Di Noto Ph.D. | Senior Vice President of Technical Operations |
| Mr. Jeetinder Singh Mahal M.B.A. | President, COO, CEO & Director |
| Mr. Matthew Ford | Senior Vice President of Human Resources |
| Mr. Thomas G. Wiggans | Executive Chairman |
| Date | Type | Document |
|---|---|---|
| 2026-04-30 | 10-K/A | ea0287356-10ka1_jasper.htm |
| 2026-03-30 | 8-K | ea0283364-8k_jasper.htm |
| 2026-03-30 | 10-K | ea0282128-10k_jasper.htm |
| 2026-01-08 | 8-K | ea0272248-8k_jasper.htm |
| 2026-01-07 | 8-K | ea0271735-8k_jasper.htm |
| 2025-12-02 | 8-K | ea0268071-8k_jasper.htm |
| 2025-11-10 | 8-K | ea0264586-8k_jasper.htm |
| 2025-09-19 | 8-K | ea0258026-8k_jasper.htm |
| 2025-08-13 | 10-Q | ea0252091-10q_jasper.htm |
| 2025-07-09 | 8-K | ea0248394-8k_jasper.htm |